YOLFTbeta
Evolus Inc

Evolus Inc

EOLS · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

6.96USD-0.22 (-3.06%)

Price History

Full chart

Market Stats

Previous Close7.18
Open7.18
Day Range6.85 – 7.18
52-Week Range3.86 – 9.31
Volume455.37K
Market Cap526.42M
P/E (TTM)0.00
Forward P/E17.01
EPS-0.53
Dividend Yield0.00%
Beta1.43
50-Day Avg7.61
200-Day Avg6.14

About

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. David Moatazedi
  • Employees353
  • Headquarters520 Newport Center Drive, Newport Beach, CA, United States, 92660, USA
  • Websitehttps://www.evolus.com

Leadership

  • Mr. David MoatazediPresident, CEO & Director · b. 1978
  • Ms. Tatjana MitchellChief Financial Officer
  • Dr. Rui Avelar C.CFP, Dip.SportMed, M.D.Chief Medical Officer and Head of Research & Development · b. 1962
  • Mr. Nareg SagherianHead of Global Investor Relations & Corporate Communications
  • Mr. Kurt KnabSenior Vice President of Sales
  • Ms. Jessica NovakSenior Vice President of Human Resources
  • Mr. Jeffrey J. PlumerCorporate Secretary

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue000034.92M56.54M99.67M148.62M202.09M266.27M297.18M
Growth (%)-----+61.89%+76.29%+49.10%+35.98%+31.76%+11.61%
Cost of Revenue416.00K326.00K218.00K08.01M18.30M43.53M58.84M61.56M83.97M104.41M
Gross Profit-416.00K-326.00K-218.00K026.91M38.24M56.14M89.77M140.53M182.30M192.76M
Gross Margin----77.05%67.64%56.32%60.41%69.54%68.46%64.86%
Operating Expense30.56M19.64M11.51M46.14M125.86M191.31M100.54M155.10M189.76M216.72M230.36M
Operating Income-30.98M-19.97M-11.73M-46.14M-98.95M-153.07M-44.41M-65.33M-49.23M-34.41M-37.60M
Operating Margin-----283.31%-270.73%-44.55%-43.96%-24.36%-12.92%-12.65%
EBITDA-30.56M-19.64M-11.51M-45.93M-92.10M-144.75M-39.06M-53.85M-41.81M-25.00M-22.53M
EBITDA Margin-----263.72%-256.02%-39.19%-36.24%-20.69%-9.39%-7.58%
Net Income-31.11M-20.07M-4.48M-46.87M-90.03M-163.01M-46.81M-74.41M-61.69M-50.42M-51.64M
Net Income Margin-----257.79%-288.31%-46.96%-50.07%-30.52%-18.94%-17.38%
R&D20.68M12.61M6.69M6.49M3.97M1.72M2.06M6.74M15.43M9.17M9.58M
R&D as % of Total Revenue----11.38%3.05%2.07%4.54%7.63%3.44%3.22%
Interest Expense000863.00K7.95M10.50M1.40M9.10M13.83M18.73M19.69M
Interest Expense % of Total Revenue----22.77%18.58%1.40%6.12%6.84%7.04%6.63%

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets81.30M77.50M152.23M171.84M240.44M209.07M257.48M177.98M189.00M232.57M225.87M
Total Liabilities69.30M84.60M227.78M87.46M160.99M282.03M175.61M159.48M209.69M227.05M248.97M
Total Equity12.00M-7.11M-75.54M84.38M79.46M-72.96M81.88M18.50M-20.69M5.52M-23.11M
Cash4.00M187.00K093.16M109.89M102.56M146.26M53.92M62.84M86.95M53.83M
Total Debt46.17M59.76M211.33M16.90M96.55M138.32M74.74M74.42M126.55M129.98M155.00M
Net Debt42.17M59.76M211.33M-76.26M-13.35M35.76M-71.51M20.50M63.71M43.03M101.17M

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-36.38M-13.27M-13.04M-25.67M-93.38M-57.87M-33.39M-84.91M-34.01M-18.00M-42.27M
Investing Cash Flow-9.00K-9.00K-9.00K-9.00K-23.43M12.19M4.03M-2.94M-1.63M-4.82M-8.45M
Financing Cash Flow36.38M13.27M13.04M118.84M133.55M38.35M73.05M-4.15M44.64M47.41M17.34M
Capital Expenditure9.00K9.00K9.00K9.00K4.57M3.14M970.00K2.94M1.63M1.47M8.45M
Free Cash Flow-36.38M-13.27M-13.04M-25.68M-97.95M-61.01M-34.36M-87.85M-35.63M-19.47M-50.72M
FCF to OCF100.00%100.00%100.00%100.04%104.89%105.42%102.91%103.46%104.78%108.18%120.00%

Earnings

Report DateMay 4, 2017Aug 28, 2017Nov 29, 2017Mar 29, 2018May 10, 2018Aug 2, 2018Nov 5, 2018Mar 18, 2019Apr 30, 2019Aug 12, 2019Nov 4, 2019Feb 25, 2020May 11, 2020Aug 10, 2020Oct 29, 2020Mar 24, 2021May 12, 2021Aug 4, 2021Nov 2, 2021Mar 3, 2022May 10, 2022Aug 2, 2022Nov 8, 2022Mar 8, 2023May 9, 2023Aug 2, 2023Nov 7, 2023Mar 7, 2024May 7, 2024Jul 31, 2024Nov 6, 2024Mar 4, 2025May 7, 2025Aug 5, 2025Nov 5, 2025Mar 3, 2026May 4, 2026Aug 5, 2026Nov 4, 2026
EPS Estimate0.000.000.00-0.30-0.36-0.32-0.42-0.55-0.62-0.84-1.14-0.68-0.62-0.69-0.37-0.22-0.43-0.25-0.27-0.21-0.33-0.24-0.29-0.15-0.16-0.20-0.18-0.07-0.08-0.06-0.110.02-0.14-0.09-0.260.04-0.12-0.09-0.14
EPS Actual-0.17-0.27-0.26-0.28-0.30-0.35-0.38-0.46-0.82-1.32-0.96-0.51-0.75-0.43-0.33-0.44-0.20-0.19-0.28-0.24-0.24-0.30-0.29-0.14-0.17-0.22-0.18-0.12-0.11-0.06-0.180.01-0.17-0.26-0.200.01-0.05-0.09-
Surprise---6.67%16.67%-9.38%9.52%16.36%-32.26%-57.14%15.79%25.00%-20.97%37.68%10.81%-100.00%53.49%24.00%-3.70%-14.29%27.27%-25.00%0.00%6.67%-6.25%-10.00%0.00%-71.43%-37.50%0.00%-63.64%-37.67%-21.43%-188.89%23.08%-64.61%58.33%0.00%-
Timing---Pre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap526.42M
Enterprise Value648.04M
Trailing P/E0.00
Forward P/E17.01
Price / Sales1.66
Price / Book53.71
EPS-0.53
Book Value-0.468
Revenue (TTM)316.49M
Gross Profit (TTM)210.16M
EBITDA-12.77M
Profit Margin-10.85%
Operating Margin-5.17%
Return on Equity-18729.61%
Return on Assets-5.68%
Shares Outstanding66.05M
Shares Float47.64M
Beta1.43
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 7 analystsTarget 15.00
  • Strong Buy
    4
  • Buy
    3

Ownership Breakdown

Institutions
77.71%
Insiders
14.48%
Retail / Other
7.81%

Top Institutional Holders

  • Nantahala Capital Management, LLC
    6.38M9.65%
  • BlackRock Inc
    4.29M6.50%
  • BRAIDWELL LP
    3.11M4.70%
  • Frazier Life Sciences Management, L.P.
    2.63M3.98%
  • Vanguard Capital Management, LLC
    2.47M3.74%
  • Perceptive Advisors LLC
    2.46M3.72%
  • Millennium Management LLC
    1.79M2.71%
  • Stonepine Capital Management Llc
    1.76M2.66%
  • Pinnacle Associates Inc
    1.49M2.25%
  • Armistice Capital, LLC
    1.40M2.11%
  • Geode Capital Management, LLC
    1.38M2.09%
  • State Street Corp
    1.32M2.00%
  • Rice Hall James & Associates, LLC
    1.29M1.95%
  • AWH Capital, L.P.
    1.25M1.89%
  • The Goldman Sachs Group Inc
    1.09M1.64%
  • Assenagon Asset Management SA
    908.18K1.38%
  • Soleus Capital Management, L.P.
    822.43K1.25%
  • Soviero Asset Management, LP
    770.00K1.17%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.54M2.34%
  • iShares Russell 2000 ETF
    1.52M2.29%